Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 7/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30932891 | 0.89 | SMN1; SMN2 (0.75) | SMN1; SMN2HSD17B10HPGDMEN1KMT2A | |
| SCHEMBL28496847 | 0.86 | SMN1; SMN2 (0.56) | SMN1; SMN2HSD17B10MEN1KMT2AALDH1A1 | |
| SCHEMBL31248363 | 0.83 | SMN1; SMN2 (0.63) | SMN1; SMN2HSD17B10HPGDKMT2AALDH1A1 | |
| SCHEMBL3556016 | 0.81 | SMN1; SMN2 (0.50) | SMN1; SMN2HSD17B10HPGDMEN1KMT2A | |
| SCHEMBL6288822 | 0.80 | TAAR1 (0.50) | SMN1; SMN2HSD17B10HPGDMEN1KMT2A | |
| SCHEMBL22604937 | 0.80 | CD274 (0.53) | MEN1KMT2AHTTGAATDP1 | |
| SCHEMBL30627676 | 0.79 | MAPT (0.57) | SMN1; SMN2HPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL14129641 | 0.78 | TSHR (0.57) | SMN1; SMN2HPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL25022061 | 0.77 | SMN1; SMN2 (0.49) | SMN1; SMN2HSD17B10HPGDMEN1KMT2A | |
| SCHEMBL25132031 | 0.77 | TAAR1 (0.58) | SMN1; SMN2HPGDGAARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825256-B2 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825256-B2 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| EP-1817030-A2 | INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS | Kalypsys, Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006060424-A2 | INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS | KALYPSYS, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | NOS3, NOS2, NOS1 | SMN1; SMN2 4446/4885HSD17B10 605/4885HPGD 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.